Abbott announced today it received CE Mark to the IVD Directive (98/79/EC) for its laboratory-based serology blood test for the detection of the antibody, IgG that identifies if a person has had the novel coronavirus (COVID-19). Antibody testing is an important next step to tell if someone has been previously infected. It will provide more understanding of the virus including how long antibodies stay in the body and if they provide immunity. This type of knowledge could help support the development of treatments and vaccines.
Narendra Varde, General Manager and Country Head at Abbott’s diagnostics business in India said, “Abbott has been singularly focused on bringing COVID-19 tests to market as quickly as possible to help address this pandemic.”
Abbott’s SARS-CoV-2 IgG test identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain up to months and possibly years after a person has recovered. Abbott’s IgG antibody test will initially be available on its ARCHITECTi1000SR and i2000SR laboratory instruments.
